FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133701998> ?p ?o ?g. }

• W3133701998 endingPage "1659" @default.
• W3133701998 startingPage "1648" @default.
• W3133701998 abstract "Autologous stem cell transplantation (ASCT) can be curative for patients with relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 monoclonal antibodies (mAbs) can sensitize patients to subsequent chemotherapy, we hypothesized that anti-PD-1 therapy before ASCT would result in acceptable outcomes among high-risk patients who progressed on or responded insufficiently to ≥1 salvage regimen, including chemorefractory patients who are traditionally considered poor ASCT candidates. We retrospectively identified 78 HL patients who underwent ASCT after receiving an anti-PD-1 mAb (alone or in combination) as third-line or later therapy across 22 centers. Chemorefractory disease was common, including 42 patients (54%) refractory to ≥2 consecutive systemic therapies immediately before anti-PD-1 treatment. Fifty-eight (74%) patients underwent ASCT after anti-PD-1 treatment, while 20 patients (26%) received additional therapy after PD-1 blockade and before ASCT. Patients received a median of 4 systemic therapies (range, 3-7) before ASCT, and 31 patients (41%) had a positive pre-ASCT positron emission tomography (PET) result. After a median post-ASCT follow-up of 19.6 months, the 18-month progression-free survival (PFS) and overall survival were 81% (95% CI, 69-89) and 96% (95% confidence interval [CI], 87-99), respectively. Favorable outcomes were observed for patients who were refractory to 2 consecutive therapies immediately before PD-1 blockade (18-month PFS, 78%), had a positive pre-ASCT PET (18-month PFS, 75%), or received ≥4 systemic therapies before ASCT (18-month PFS, 73%), while PD-1 nonresponders had inferior outcomes (18-month PFS, 51%). In this high-risk cohort, ASCT after anti-PD-1 therapy was associated with excellent outcomes, even among heavily pretreated, previously chemorefractory patients." @default.
• W3133701998 created "2021-03-15" @default.
• W3133701998 creator A5000703445 @default.
• W3133701998 creator A5001231553 @default.
• W3133701998 creator A5004343197 @default.
• W3133701998 creator A5005058090 @default.
• W3133701998 creator A5005281918 @default.
• W3133701998 creator A5007477825 @default.
• W3133701998 creator A5007601060 @default.
• W3133701998 creator A5013911840 @default.
• W3133701998 creator A5015287155 @default.
• W3133701998 creator A5020852034 @default.
• W3133701998 creator A5024389256 @default.
• W3133701998 creator A5028590331 @default.
• W3133701998 creator A5029237145 @default.
• W3133701998 creator A5030788778 @default.
• W3133701998 creator A5031812464 @default.
• W3133701998 creator A5034653699 @default.
• W3133701998 creator A5036228481 @default.
• W3133701998 creator A5040815890 @default.
• W3133701998 creator A5051862003 @default.
• W3133701998 creator A5052064208 @default.
• W3133701998 creator A5052962596 @default.
• W3133701998 creator A5059729547 @default.
• W3133701998 creator A5060314041 @default.
• W3133701998 creator A5062691289 @default.
• W3133701998 creator A5064556004 @default.
• W3133701998 creator A5065588144 @default.
• W3133701998 creator A5067489954 @default.
• W3133701998 creator A5071407925 @default.
• W3133701998 creator A5071416130 @default.
• W3133701998 creator A5071711909 @default.
• W3133701998 creator A5075285981 @default.
• W3133701998 creator A5076036129 @default.
• W3133701998 creator A5077386322 @default.
• W3133701998 creator A5078448821 @default.
• W3133701998 creator A5080192231 @default.
• W3133701998 creator A5084789778 @default.
• W3133701998 creator A5085684983 @default.
• W3133701998 creator A5085801543 @default.
• W3133701998 creator A5085821011 @default.
• W3133701998 creator A5086211539 @default.
• W3133701998 creator A5086490383 @default.
• W3133701998 creator A5088459737 @default.
• W3133701998 date "2021-03-12" @default.
• W3133701998 modified "2023-10-01" @default.
• W3133701998 title "Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma" @default.
• W3133701998 cites W1558461926 @default.
• W3133701998 cites W1860199933 @default.
• W3133701998 cites W1978849352 @default.
• W3133701998 cites W1980320803 @default.
• W3133701998 cites W1993091132 @default.
• W3133701998 cites W2000153687 @default.
• W3133701998 cites W2004678634 @default.
• W3133701998 cites W2024626926 @default.
• W3133701998 cites W2034841280 @default.
• W3133701998 cites W2064827653 @default.
• W3133701998 cites W2071134744 @default.
• W3133701998 cites W2078178842 @default.
• W3133701998 cites W2079315541 @default.
• W3133701998 cites W2084381708 @default.
• W3133701998 cites W2084924278 @default.
• W3133701998 cites W2111070506 @default.
• W3133701998 cites W2112065237 @default.
• W3133701998 cites W2119147717 @default.
• W3133701998 cites W2125616358 @default.
• W3133701998 cites W2129453071 @default.
• W3133701998 cites W2141082026 @default.
• W3133701998 cites W2157717016 @default.
• W3133701998 cites W2164526402 @default.
• W3133701998 cites W2233814136 @default.
• W3133701998 cites W2252550602 @default.
• W3133701998 cites W2473498748 @default.
• W3133701998 cites W2500482667 @default.
• W3133701998 cites W2514468425 @default.
• W3133701998 cites W2567998110 @default.
• W3133701998 cites W2598700764 @default.
• W3133701998 cites W2604580699 @default.
• W3133701998 cites W2743577629 @default.
• W3133701998 cites W2745549673 @default.
• W3133701998 cites W2791794278 @default.
• W3133701998 cites W2794872274 @default.
• W3133701998 cites W2802434483 @default.
• W3133701998 cites W2806213952 @default.
• W3133701998 cites W2892881565 @default.
• W3133701998 cites W2917630208 @default.
• W3133701998 cites W2945661283 @default.
• W3133701998 cites W2946038977 @default.
• W3133701998 cites W2968942240 @default.
• W3133701998 cites W2973186521 @default.
• W3133701998 cites W2983129895 @default.
• W3133701998 cites W2991161627 @default.
• W3133701998 cites W3016237720 @default.
• W3133701998 cites W3027036348 @default.
• W3133701998 cites W3046214598 @default.
• W3133701998 doi "https://doi.org/10.1182/bloodadvances.2020003556" @default.
• W3133701998 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7993097" @default.
• W3133701998 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33710337" @default.

• next